PEAK PROCESSING LIMITED — Capital/Financing Update 2021

Feb 10, 2021

==> picture [596 x 149] intentionally omitted <==

ASX Announcement | 11 February 2021 Althea Group Holdings (ASX:AGH)

Althea completes first export of products to Grow Pharma

Investment Highlights:

• Althea has completed its first export shipment of products to UK-based medicinal cannabis distributor Grow Pharma

• Signed in 2020, the medicinal cannabis supply agreement allows Grow Pharma to distribute Althea products in the UK, in parallel to the Company’s own sales channel

• Althea recently expanded its agreement with Grow Pharma to include two further jurisdictions, including the Isle of Man and Guernsey

11 February 2021: Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce that it has completed the export of its first commercial shipment of Althea products to UK-based medicinal cannabis distributor Grow Pharma Group ( ‘Grow Pharma’ ).

A medicinal cannabis supply agreement was signed by the two parties last year, allowing Grow Pharma to distribute Althea products in the UK, in parallel to the Company’s own existing sales channel. Following initial success with products supplied to Grow Pharma from its UK inventory, Althea recently expanded its agreement with Grow Pharma to include two further jurisdictions, including the Isle of Man and Guernsey.

The Isle of Man and Guernsey are self-governing dependencies of the Crown and medicinal cannabis has been legal in both territories since 2018 and 2019, respectively.

Grow Pharma CEO, Pierre van Weperen said: “Grow Pharma is a leading distributor of medical cannabis in the UK and is working with the world’s best producers of cannabis-based medicines to bring their products to exciting new markets such as the UK, Isle of Man, Guernsey and Ireland. The Althea manufacturing team have been consummate professionals throughout the quality and regulatory process required to import their products into the UK and we look forward to servicing patients with their high-quality and affordable medicines.”

Althea CEO, Joshua Fegan said: “We are very pleased to have completed our initial shipment of products to Grow Pharma in the UK. Whilst the Althea brand has been in the UK for some time now and is experiencing early success, we are very proud to work with local distributors like Grow Pharma to help accelerate industry growth and ultimately service more patients. Europe is fast becoming a global hub for medicinal cannabis, and is leading the world in patient access, regulatory affairs, and product sales. With operations in the UK and Germany, Althea is at the forefront of this next frontier.”

-ENDS-

==> picture [596 x 91] intentionally omitted <==

==> picture [596 x 149] intentionally omitted <==

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea Media Enquiries Investor Relations Josh Fegan Dan Francome Lelde Smits CEO & Managing Director Media Relations Investor Relations Partner M: 1300 70 20 20 P: +613 9650 5096 M: +61 434 056 539 E: contact@althea.life E: dfrancome@althea.life E: lelde@thecapitalnetwork.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global pharmaceutical company and supplier of medicinal cannabis. Althea also offers a range of education, access and management services to support eligible patients and Healthcare Professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia, United Kingdom and Germany, with plans to expand the brand into emerging markets across the world.

To learn more, please visit: www.althea.life

==> picture [596 x 91] intentionally omitted <==